Ketoprofen topical

Current status:
European Commission final decision

Overview

Outcome of a procedure under Article 107 of Directive 2001/83/EC

The European Medicines Agency has completed a review of the safety and effectiveness of ketoprofen-containing medicines used topically (on the skin). The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of topical ketoprofen continue to outweigh its risks, but that further measures should be put in place to minimise the risk of adverse skin reactions.

Key facts

Approved name
Ketoprofen topical
International non-proprietary name (INN) or common name
ketoprofen
Associated names
  • Fastum
  • Ketum
  • Orudis
Reference number
EMEA/H/A-107/001259
Type
Article 107 procedures (prior to July 2012)

This type of procedure was triggered when a Member State varied, suspended or revoked the marketing authorisation for a medicine in its territory because of a safety issue. This procedure has been replaced by Article 107i.

Status
European Commission final decision
Opinion date
22/07/2010
EC decision date
29/11/2010

All documents

Document description

  • Questions and answers (Q&A) - easy-to-understand summary of key issues and Committee conclusions
  • Summary of Opinion - contains the CHMP opinion of the referred medicine(s)
  • List of the medicines affected by the referral (Annex I)
  • Scientific conclusions of the Committee (Annex II)

The following two documents are sometimes available:

  • Changes to the summary of product characteristics, labeling or package leaflet (also known as Annex III) - available when changes havebeen recommended by the Committee
  • Conditions of the marketing authorisation (also known as Annex IV) - available when the Committee recommends measures to be takenfor the marketing authorisation(s) such as safety measures or extra studies

How useful was this page?

Add your rating